Q-omics provides the consensus-scored ETHE1 profile across patient tissues and cancer cell-line models. ETHE1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ETHE1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ETHE1 protein abundance shows 28,934 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, THCA, and GBM as cancer lineages where ETHE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETHE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETHE1 survival associations across molecular data types. ETHE1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETHE1 RNA expression–survival associations across cancer types. High ETHE1 expression shows unfavorable associations in KIRP, ACC, LUAD, LGG and KIRC, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for ETHE1 RNA expression.
This table summarizes ETHE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ETHE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETHE1 shows lower tumor expression in COAD, READ and KICH and higher tumor expression in THCA, KIRP and STAD. The THCA box plot shows higher ETHE1 RNA expression in tumor versus normal tissue (log2 FC = +1.592, t-test p < 0.001).
This table shows molecular features associated with ETHE1 in patient tissues and cancer cell lines. In patient samples, ETHE1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ETHE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
